BreAking the Link betweeN myo10 and CancEr

Project Information

BALaNCE

Grant agreement ID: 641346

DOI

10.3030/641346

Project closed

EC signature date 20 April 2015

Start date 1 May 2015

End date 31 October 2016

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 150 000,00

EU contribution

€ 150 000,00

Coordinated by

TURUN YLIOPISTO
Finland

Periodic Reporting for period 1 - BALaNCE (BreAking the Link betweeN myo10 and CancEr)

Reporting period: 2015-05-01 to 2016-10-31

Summary of the context and overall objectives of the project

Metastasis is the main cause for cancer morbidity as spread of the cancer cells from their primary site to distant organs is currently difficult, or impossible, to treat. We have found earlier that several proteins regulating actin-rich protrusions, called filopodia, are overexpressed in spreading cancers, like breast and pancreatic cancers. One of the proteins driving these filopodia is Myo10, an actin and integrin binding motor protein. The aim of this project was to generate solid evidence that inhibiting Myo10 is an effective strategy to combat cancer spread. During this project we have used drug screening and different cancer metastasis models and validated that indeed Myo10 inhibition is a viable option for cancer therapy. As an outcome we have secured a partnership to start developing new Myo10 inhibitors against cancer.